Bayer Battles New Insecticide Research Affecting 20% of Sales
at The Street - Wed Jul 23, 9:18AM CDT
Bayer CropSciences' corn seed treatments and flea and tick medicine for pets may be killing birds and bees. The company stands to lose big if the chemical is banned.
Global Women's Health Market 2014-2018
M2 - Wed Jul 23, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kxqgp/global_womens) has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering. The Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018. Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men. Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment: - Postmenopausal Osteoporosis (Drugs) - Hormonal Contraceptives (Drugs and Devices) - Menopause (Drugs) - Infertility (Drugs) - Endometriosis (Drugs) - Polycystic Ovary Syndrome (Drugs) The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Bayer AG - Eli Lilly and Co. - Merck & Co. - Pfizer Inc. According to the report, the growth of the Global Women's Health market is curtailed by some serious challenges. One of the main challenges is the patent expiry of major blockbuster drugs during the forecast period. Some of the patent expiries of top leading products include Bayer's Mirena and Yaz, Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva. For more information visit http://www.researchandmarkets.com/research/4k...bal_womens
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Animal Antimicrobials and Antibiotics (Tetracyclines, Penicillins, Sulfonamides, Aminoglycosides) Market 2014-2018
M2 - Wed Jul 23, 4:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hmcm5/animal) has announced the addition of the "Animal Antimicrobials and Antibiotics Market by Products, Animals & Mode Of Delivery - Global Forecasts to 2018" report to their offering. At present, the global antimicrobials and antibiotics market is driven by the growing need to preserve animal health owing to rising demand for animal proteins across the globe, and growing demand in the companion animals segment. Growing livestock population, increasing incidences of disease outbreaks and increase in the companion animal ownership are some of the factors driving the growth of this market to a certain extent. Besides the structural market drivers, there are strong geographic drivers for the growth of the animal antimicrobials and antibiotics market. Emerging markets are becoming increasingly attractive. The Asian and Latin American region form one of the most promising animal antimicrobials and antibiotics markets in the world. Developing countries such as China and India have a relatively high CAGR rate and are expected to witness significant market growth in the forecast period. The growth in these regions is mainly attributed to the rise in demand for animal protein products, along with an increase in the trend of companion animal ownership in these regions. Today, the animal antimicrobials and antibiotics market showcase a sluggish growth, owing to the regulatory authorities restricting their use, increased usage of in-feed enzymes, competitive exclusion products and probiotics as an alternative to antibiotics and prophylactic use of antibiotics being replaced by good husbandry, environment and hygienic practices. Report Scope Products - Tetracyclines - Penicillins - Sulfonamides - Aminoglycosides Animals - Dog - Poultry - Swine Mode Of Delivery - Premixes - Oral Powders - Solutions - Injections Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Veterinary Antimicrobials And Antibiotics Market, By Product 6 Veterinary Antimicrobials And Antibiotics Market, By Mode Of Delivery 7 Veterinary Antimicrobials And Antibiotics Market, By Type Of Animal 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned - Bayer Ag - Boehringer Ingelheim - Ceva Sante Animale - Eli Lilly And Company - Merck And Co., Inc. - Novartis Ag - Sanofi - Vetoquinol - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/4hmcm5/animal
Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:20PM CDT
Bayer (BAYRY) and Regeneron Pharmaceuticals (REGN) announced encouraging results from the phase III study on Eylea.
2014 Global Non-Hodgkin Lymphoma Therapeutics Market Report Featuring Bristol Myers Squibb, Celgen, Eli Lilly and Co, F. Hoffman La-Roche & GSK
M2 - Tue Jul 22, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52q7th/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests. This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market. The report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Celgene Corp. - Eli Lilly and Co. - F. Hoffman La-Roche Ltd. - GlaxoSmithKline plc Other Prominent Vendors - Accredo Health Group Inc. - Baxter International Inc. - Bayer AG - Cephalon Inc. - Eisai Pharmaceuticals Inc. - Genelabs Technologies Inc. - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Millenium Pharmaceuticals Inc. - Pacira Pharmaceuticals Inc. - Pfizer Inc. - Sanofi SA - Teva Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/52q7th/global
Global Gynecological Devices Market to 2018: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instrument
M2 - Mon Jul 21, 8:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n4f66s/global) has announced the addition of the "Global Gynecological Devices Market 2014-2018" report to their offering. The Global Gynecological Devices market will grow at a CAGR of 6.63 percent over the period 2014-2018. Gynecological devices have been broadly classified into wide categories based on their operations. These devices are used for the treatment of different gynecological conditions that affect the female reproduction organs, female fertility, menorrhagia (heavy menstrual periods), infections, and disorders such as endometriosis, gestational diabetes, polycystic ovary syndrome, uterine fibroids, and pelvic floor disorders. Every woman faces a gynecological condition at some point in her life. Several conditions may be easily treatable and several may be life threatening. The gynecological devices help by having an impact on a woman's infertility , treat serious illnesses, and treat the devastating consequences that are life threatening. The gynecological devices are made to perform with advanced technologies and procedures to improve the treatment of complex gynecology surgeries. Several devices are portable, disposable, and very easy to handle and can be used in any gynecology centers. This report covers the present scenario and the growth prospects of the Global Gynecological Devices market for the period 2014-2018. The Global Gynecological Devices market can be segmented into four divisions: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instruments. These are sets of methodologies and technologies that transform unstructured and structured data into meaningful and useful information processes. The report, the Global Gynecological Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gynecological Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bayer AG - Boston Scientific Corp. - CooperSurgical Inc. - Ethicon Inc. - Hologic Inc. - Medtronic Inc. - Olympus Corp. - Stryker Corp. Other Prominent Vendors - ATMOS MedizinTechnik GmbH & Co. KG - BTL Medical technologies Inc. - KARL STORZ GmbH & Co. KG - Meditelle Medical Equipment Ltd. - Richard Wolf GmbH - Welch Allyn, Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/n4f66s/global
New Study Touts Benefits of Organic Goods, Questions Pesticides and GMOs
Brian Stoffel, The Motley Fool - Motley Fool - Sat Jul 19, 9:24AM CDT
Scientists estimate that we humans—since our earliest ancestors—have been running around the earth for well over two million years. Only within the past century—or 0.005% of that time—have we come to rely so heavily on the use of pesticides to help...
Research and Markets: Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
Business Wire - Thu Jul 17, 1:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9d5hv/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering.
Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
M2 - Thu Jul 17, 10:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8lcbs/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering. This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market. The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market. According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market. Further, the report states that one of the main challenges is patent expiries of endometriosis drugs which leads to loss of exclusive rights of branded products followed by the introduction of low-priced generics into the market. This poses a potential threat to the established companies that spend a huge amount on R&D. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Abbvie Inc. - AstraZeneca plc - Bayer AG - Pfizer Inc. Other Prominent Vendors - Astellas Pharma Inc. - Abbvie Inc. - Repros Therapeutics Inc. - Sanofi SA - Takeda Pharmaceuticals Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Market Segmentation by Route of Administration and Type of Dosage Form - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/k8lcbs/global
American Commercial Lines Presents Marine Environmental Stewardship Award to Customers for Safe Handling of Chemicals, Petroleum Products, and Other Liquid Cargoes
Marketwire - Wed Jul 16, 10:44AM CDT
American Commercial Lines Inc. ("ACL" or the "Company"
Global Transdermal Drug Delivery Market 2014-2018 with ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen Pharma & Novartis Dominating
M2 - Wed Jul 16, 9:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sz2mh3/global) has announced the addition of the "Global Transdermal Drug Delivery Market 2014-2018" report to their offering. The Global Transdermal Drug Delivery market will grow at a CAGR of 9.9% Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin. This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: - Smoking Cessation - Pain Management - Hormone Therapy - Cardiovascular Indications - Others Key Vendors - ANI Pharmaceuticals Inc. - Antares Pharma Inc. - Bayer AG - Janssen Pharmaceuticals Inc. - Novartis AG Other Prominent Vendors - 3M Pharmaceuticals Co. - Durect Corp. - Iontera Inc. - Isis Biopolymer Inc. - LTS Lohmann Therapie-Systeme AG - Mylan Laboratories Inc. - Nitto Denko Corp. - Pantec Biosolutions AG - Phosphagenics Ltd. - Tesa Labtec GmbH - Teva Pharmaceutical Industries Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Competitive Assessment of Transdermal Drugs Delivery Market - Optimisation of Transdermal Drug Delivery - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/sz2mh3/global
Malini Moorthy Joins Bayer as U.S. Head of Litigation
PR Newswire - Tue Jul 15, 10:00AM CDT
Bayer Corporation today announced the appointment of Malini Moorthy as Head of the Litigation Department in the United States, effective July 30. She succeeds Kaspar Stoffelmayr, whose three-year assignment ended and has rejoined Bartlit Beck Herman Palenchar & Scott LLP.
Global Agrochemicals Market 2014-2018: Key Vendors are BASF, Bayer AG, Dow AgroSciences, Potash Corp. of Saskatchewan, Syngenta, The Mosaic and Yara International
PR Newswire Europe - Mon Jul 14, 7:10AM CDT
Research and Markets [http://www.researchandmarkets.com/research/3vkkmq/global] has announced the addition of the "Global Agrochemicals Market 2014-2018" [http://www.researchandmarkets.com/research/3vkkmq/global] report to their offering.
Global Animal Parasiticides Market Report 2014-2018: Product & Animal Breakdown of the $8.6 Billion Market
M2 - Mon Jul 14, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2jh2xt/animal) has announced the addition of the "Animal Parasiticides Market by Product & Animal - Global Forecast to 2018" report to their offering. The market is expected to grow at a CAGR of 5.4% from 2013 to 2018 to reach $8.4 billion by 2018 In this report, the global animal parasiticides market is broadly segmented by product type, animal type, and geography. By product type, the animal parasiticides are classified into three major segments, namely, endoparasiticides, ectoparasiticides, and endectocides. These product segments are further sub-segmented depending on the formulation type. The endoparasiticides are classified into feed additives, injectables, oral liquids, tablets (oral solids), and other. The overall growth in the animal parasiticides market is largely driven by rising concerns regarding zoonotic diseases; an upsurge in the investment from government organizations, non-government agencies, and leading market players; increasing demand for animal protein and animal-based food, especially in the emerging markets in APAC and Latin American region; implementation of animal welfare acts in developed countries; availability of new broad spectrum parasiticides product offerings from leading players; and an upsurge in the adoption of pet animals. However, stringent regulations for registration and approval of animal parasiticides, restrictions on the use of parasiticides in food producing animals, expensive and time consuming R&D activities to develop a new product, restriction on the use of specific parasiticides in certain countries, emerging species of parasites with resistance to existing parasiticidal agents restrict the growth of the market to a certain extent. Veterinary pharmaceuticals including parasiticides have transformed the health of companion and livestock animals across the globe in the past two decades. Today, the spectrum of parasiticides for the veterinary applications continues to expand with variety of ectoparasiticides, endoparasiticides, and endectocides being launched every year. The innovations are leading to emergence of novel parasiticide delivery systems as well. Protection of animals from parasitic infestations has also gained greater importance in animal parasiticides market over the years. Scope Product - Endoparasiticides - Ectoparasiticides - Endectocides - Oral Liquids - Tablets - Injectables - Sprays - Pour On - Spot On - Collars - Ear Tags Animal - Dogs - Cats - Cattle - Pigs - Sheep - Goats Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Animal Parasiticides Market, By Product Type 5 Global Animal Parasiticides Market, By Type Of Animal 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles - Bayer Ag - Boehringer Ingelheim - Ceva Sante Animale - Eli Lilly And Company - Merck & Co., Inc. - Novartis Ag - Sanofi - Vetoquinol - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/2jh2xt/animal
Global Animal Growth Promoters and Performance Enhancers Market Report 2014-2018
M2 - Fri Jul 11, 2:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4drwgt/animal_growth) has announced the addition of the "Global Animal Growth Promoters and Performance Enhancers Market Report 2014-2018" report to their offering. Antibiotics was the largest segment of the animal growth promoters market and was valued at $4,489.7 million in 2013 However, feed enzymes are expected to grow at the fastest rate owing to the increasing popularity and demand for alternatives to antibiotic and hormonal growth promoters. The animal growth promoters and performance enhancers market is segmented into antibiotics/antimicrobials, probiotics and prebiotics, organic acids, feed enzymes, hormonal growth promonants, ?-agonists, phytogenics, and others. These growth promoters are used in the animal feed to increase their growth and to enhance their performance. The animal growth promoters and performance enhancers market, by animal industry is segmented into porcine, poultry, livestock, equine, and aquaculture. The porcine industry made use of the largest amount of growth promoters, in 2013, followed by poultry and livestock. The changing consumption trend globally is likely to increase the demand for pork meat, thus making more use of the growth promoters. Countries such as Brazil, Australia, and New Zealand in the RoW region are also expected to witness growth in this market, owing to very little regulations on the use of growth promoters in animals and the increasing meat demand. The global animal growth promoters and performance enhancers market witness's high competitive intensity as there are many big and small firms with similar product offerings. These companies adopt various strategies to increase their market share and to establish a strong foothold in the global market. However, increasing awareness amongst consumers regarding the hazards of using antibiotic growth promoters and their ban are likely to hamper the growth of this market. The report extensively covers the animal growth promoters and performance enhancers market (products and animals). Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Animal Performance Enhancers Market, By Product 5 Global Animal Performance Enhancers Market, By Animal 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles - Bayer Animal Health (A Subsidiary of Bayer Ag) - Biomin Holding Gmbh - Bioniche Animal Health (A Division of Bioniche Life Sciences, Inc.) - Boehringer Ingelheim - Bupo Animal Health (PTY) - Cargill, Inc. - Elanco Animal Health (A Division of Eli Lilly and Company) - Merck Animal Health (A Subsidiary of Merck & Co., Inc.) - Royal Dsm N.V. - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/4d...mal_growth
Bayer Presents $50,000 Science Education Grant To Honorary President Of The Police Athletic League (PAL), NYC Police Commissioner William J. Bratton, In Support Of PAL Programs
PR Newswire - Wed Jul 09, 12:46PM CDT
As part of its three-day Science For A Better Life interactive experience at historic Grand Central Terminal, Bayer Corporation today presented New York City Police Commissioner William J. Bratton with a $50,000 donation to the Police Athletic League of New York City (PAL) in support of its STEM (science, technology, engineering and mathematics) educational programs.
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
Global Agrochemicals Market 2014-2018 with BASF, Bayer, Dow AgroSciences, Potash Corp. of Saskatchewan, Syngenta, The Mosaic Co. & Yara International Dominating
M2 - Mon Jul 07, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pcs93x/global) has announced the addition of the "Global Agrochemicals Market 2014-2018" report to their offering. The Global Agrochemicals market to grow at a CAGR of 4.16 percent over the period 2013-2018. According to the report, because of a steady increase in global population and economic development in several countries, per capita disposable income has increased globally. This has resulted in an increase in the demand for food, especially high-quality nutritious food, thus driving the Global Agrochemicals market. Further, the report states that despite the presence of several drivers, there are some constraints on the Global Agrochemicals market. The expiry of patents of over 20 active ingredients during the forecast period could adversely affect market growth, as this could lead to the introduction of low-cost generic ingredients, thereby reducing market size. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - BASF SE - Bayer AG - Dow AgroSciences - Potash Corp. of Saskatchewan Inc. - Syngenta AG - The Mosaic Co. - Yara International ASA Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Global Agrochemicals Market - Global Pesticides Market - Global Fertilizers Market - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/pcs93x/global